XML 20 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Assets [Abstract]    
Land $ 16,390,250 $ 15,983,323
Buildings and improvements 101,878,107 102,862,977
Tenant improvements 17,645,103 16,488,066
Lease intangibles 3,467,798 3,776,654
Real estate assets and lease intangibles held for investment, cost 139,381,258 139,111,020
Accumulated depreciation and amortization (37,536,809) (33,700,262)
Real estate assets and lease intangibles held for investment, net 101,844,449 105,410,758
Real estate assets held for sale, net 6,805,255 22,185,742
Real estate assets, net 108,649,704 127,596,500
Other assets:    
Cash, cash equivalents and restricted cash 7,422,359 8,036,496
Deferred leasing costs, net 1,340,853 1,666,135
Goodwill 1,317,000 1,389,000
Investment in Conduit Pharmaceuticals marketable securities (see Notes 2 & 9) 3,900 206,177
Deferred tax asset 223,388 298,645
Other Assets, Miscellaneous 3,095,670 3,376,697
Total other assets 13,403,170 14,973,150
TOTAL ASSETS [1] 122,052,874 142,569,650
Liabilities:    
Mortgage notes payable, net 81,936,586 80,977,448
Mortgage notes payable related to properties held for sale, net 10,137,781 21,116,646
Mortgage notes payable, total net 92,074,367 102,094,094
Accounts payable and accrued liabilities 3,302,187 3,290,170
Accrued real estate taxes 1,785,029 1,972,477
Dividends payable - Preferred Stock Series D 190,220 194,784
Lease liability, net 40,108 64,345
Below-market leases, net 3,316 8,625
Total liabilities 97,395,227 107,624,495
Commitments and contingencies (see Note 10)
Equity:    
Additional paid-in capital 186,762,388 185,770,842
Dividends and accumulated losses (169,945,302) (159,374,010)
Total stockholders' equity before noncontrolling interest 16,839,965 26,535,146
Noncontrolling interest 7,817,682 8,410,009
Total equity 24,657,647 34,945,155
TOTAL LIABILITIES AND EQUITY 122,052,874 142,569,650
Series D Preferred Stock [Member]    
Liabilities:    
Dividends payable - Preferred Stock Series D 190,220 194,784
Equity:    
Series D Preferred Stock, $0.01 par value per share; 1,000,000 shares authorized; 973,736 shares issued and outstanding (liquidation preference $25.00 per share) as of December 31, 2025 and 997,082 shares issued and outstanding as of December 31, 2024 9,737 9,971
Common Class A [Member]    
Equity:    
Series A Common Stock, $0.01 par value per share, shares authorized: 100,000,000; 1,313,832 shares and 1,283,432 shares were issued and outstanding at December 31, 2025 and December 31, 2024, respectively $ 13,142 $ 128,343
[1] As of December 31, 2025 and 2024, includes approximately $8.6 million and $11.4 million, respectively, of assets related to consolidated variable interest entities that can be used only to settle obligations of the consolidated variable interest entities.